$899 Billion is the total value of SENZAR ASSET MANAGEMENT, LLC's 82 reported holdings in Q4 2015. The portfolio turnover from Q3 2015 to Q4 2015 was 50.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NVRO | Sell | NEVRO CORP | $113,611,026,000 | +11.1% | 1,682,877 | -23.7% | 12.63% | -15.1% |
| MYL | Sell | MYLAN N V | $42,460,306,000 | -38.7% | 785,284 | -54.3% | 4.72% | -53.1% |
| STJ | Sell | ST JUDE MED INC | $31,311,213,000 | -43.0% | 506,900 | -41.8% | 3.48% | -56.4% |
| CNCE | Sell | CONCERT PHARMACEUTICALS INC | $27,176,744,000 | -12.0% | 1,432,617 | -12.9% | 3.02% | -32.7% |
| BIIB | Sell | BIOGEN INC | $26,438,005,000 | +1.2% | 86,300 | -3.6% | 2.94% | -22.6% |
| MNKKQ | Sell | MALLINCKRODT PUB LTD CO | $21,787,482,000 | -20.8% | 291,940 | -32.1% | 2.42% | -39.5% |
| ITCI | Sell | INTRA CELLULAR THERAPIES INC | $18,983,782,000 | -14.8% | 352,924 | -36.6% | 2.11% | -34.8% |
| DERM | Sell | DERMIRA INC | $8,565,975,000 | +24.3% | 247,500 | -16.2% | 0.95% | -5.1% |
| XOMA | Exit | XOMA CORP DEL | $0 | – | -2,327,100 | -100.0% | -0.25% | – |
| FLDM | Exit | FLUIDIGM CORP DEL | $0 | – | -310,587 | -100.0% | -0.37% | – |
| MDXG | Exit | MIMEDX GROUP INC | $0 | – | -416,361 | -100.0% | -0.58% | – |
| ACHN | Exit | ACHILLION PHARMACEUTICALS IN | $0 | – | -619,000 | -100.0% | -0.62% | – |
| OFIX | Exit | ORTHOFIX INTL N V | $0 | – | -134,984 | -100.0% | -0.66% | – |
| XNPT | Exit | XENOPORT INC | $0 | – | -2,150,090 | -100.0% | -1.08% | – |
| CI | Exit | CIGNA CORPORATION | $0 | – | -173,600 | -100.0% | -3.41% | – |
| AMGN | Exit | AMGEN INC | $0 | – | -207,400 | -100.0% | -4.17% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-02-12
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CONCERT PHARMACEUTICALS INC | 16 | Q2 2018 | 4.5% |
| SANOFI | 14 | Q2 2018 | 17.6% |
| CORIUM INTL INC | 14 | Q3 2017 | 2.3% |
| FOAMIX PHARMACEUTICALS LTD | 14 | Q2 2018 | 2.1% |
| RETROPHIN INC | 13 | Q2 2017 | 3.0% |
| ALDER BIOPHARMACEUTICALS INC | 12 | Q2 2018 | 3.9% |
| RIGEL PHARMACEUTICALS INC | 12 | Q3 2016 | 1.8% |
| INSMED INC | 11 | Q3 2017 | 6.2% |
| TEVA PHARMACEUTICAL INDS LTD | 10 | Q1 2016 | 12.3% |
| ORTHOFIX INTL N V | 10 | Q1 2017 | 9.0% |
View SENZAR ASSET MANAGEMENT, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Corium International, Inc.Sold out | February 14, 2018 | 0 | 0.0% |
| Aviragen Therapeutics, Inc. | February 13, 2017 | 1,774,876 | 4.6% |
| CONCERT PHARMACEUTICALS, INC. | February 13, 2017 | 400,588 | 1.8% |
| Foamix Pharmaceuticals Ltd. | February 13, 2017 | 550,997 | 1.5% |
| NEVRO CORPSold out | February 13, 2017 | 0 | 0.0% |
| TIVITY HEALTH, INC. | February 13, 2017 | 383,200 | 1.0% |
| HEALTHWAYS, INC | February 12, 2016 | 2,525,044 | 7.0% |
| Sientra, Inc. | February 12, 2016 | 580,851 | 3.2% |
| Biota Pharmaceuticals, Inc. | January 15, 2016 | 2,025,976 | 5.2% |
View SENZAR ASSET MANAGEMENT, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2018-10-31 |
| 13F-HR | 2018-08-13 |
| 13F-HR | 2018-05-14 |
| SC 13G/A | 2018-02-14 |
| 13F-HR | 2018-02-13 |
| 13F-HR | 2017-11-13 |
| 13F-HR | 2017-08-11 |
| 13F-HR | 2017-05-12 |
| 13F-HR | 2017-02-14 |
| SC 13G/A | 2017-02-13 |
View SENZAR ASSET MANAGEMENT, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.